Advancements in Non-Small-Cell Lung Cancer Management
Discover the latest advancements in non-small-cell lung cancer (NSCLC) management, including improved screening techniques, innovative surgical methods, and novel treatment options like targeted therapies and immunotherapy. Learn how these developments are enhancing patient outcomes and survival rates, and the importance of personalized medicine in NSCLC treatment.
Study Shows IMRT Superior to 3D-CRT for Lung Cancer Treatment
Learn how intensity-modulated radiation therapy (IMRT) can benefit patients with non-small cell lung cancer (NSCLC) compared to 3D-conformal radiation therapy (3D-CRT). A recent study from The University of Texas MD Anderson Cancer Centre highlights the accuracy and reduced adverse effects of IMRT, recommending its standard use for locally advanced, unresectable NSCLC. Lead author Stephen Chun, M.D., emphasizes the significance of IMRT in improving treatment outcomes for patients with lung cancer.
Recent Updates from CROWN Trial: Lorlatinib in Treatment-Naïve Patients with Advanced ALK+ NSCLC
Learn about the recent updates from the CROWN trial on lorlatinib in treatment-naïve patients with advanced ALK+ NSCLC. Expert perspectives from The Oncology Brothers and Joshua K. Sabari, MD, shed light on the efficacy of lorlatinib and its potential as a groundbreaking treatment option for this specific patient population. Discover the promising outcomes and favorable response rates observed, emphasizing the importance of early intervention with lorlatinib in managing advanced ALK+ NSCLC.
Johnson & Johnson’s Injectable Rybrevant Shows Promise in Extending Lives of Lung Cancer Patients
Johnson & Johnson’s injectable Rybrevant has shown promising results in extending the lives of lung cancer patients, with a 38% reduction in the risk of death compared to the intravenous version. The subcutaneous formulation demonstrated better overall survival, longer duration of response, and lower infusion-related reactions. With plans to file for FDA approval, J&J aims to gain a competitive edge in the market against AstraZeneca’s Tagrisso.
Gilead stock falls 10% after disappointing lung cancer drug trial results
Shares of Gilead took a hit as the stock fell more than 10% on Monday following disappointing results from a late-stage trial of its key lung cancer drug, Trodelvy. The trial failed to significantly extend the lives of patients with…